|
|
|
|
|
|
|
|
abstract (Korea)
Highlights
- •
- We explored patients' preferences for adding bevacizumab to first-line therapy.
- •
- A discrete choice experiment and trade-off question were designed and distributed to ovarian cancer patients.
- •
- Patients' preferences for bevacizumab depend primarily on drug costs.
Background
The
GOG-218 and ICON-7 studies recently showed that adding bevacizumab to
first-line therapy for patients with advanced ovarian cancer increased
progression-free survival. However, the high cost and long treatment
duration prevents the incorporation of bevacizumab in practice. The aim
of this study was to explore and quantify patients' preferences for
adding bevacizumab to first-line therapy.
Methods
A
discrete choice experiment (DCE) and trade-off question were designed
and distributed to 102 ovarian cancer patients. Participants were asked
to choose between two hypothetical first-line therapies that differed in
terms of effectiveness, safety, and the financial burden. A trade-off
technique varying the cost of bevacizumab was used to quantify a
willingness-to-pay threshold for selecting bevacizumab.
Results
All
attributes of the DCE had a statistically significant impact on
respondents' preferences and the financial burden was the most important
attribute. The results of the trade-off question showed that more than
half of patients would prefer to add bevacizumab to standard
chemotherapy when the cost of the drug was reduced to 17% (1/6) of the
baseline cost.
Conclusion
Patients'
preferences for bevacizumab in the adjuvant treatment of ovarian cancer
depend primarily on drug costs. Our results suggest that the current
cost of bevacizumab is sufficiently high that the majority of ovarian
cancer patients are not willing to pay to accept a small increase in
progression-free survival.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.